Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment
Concetta Meo,Giuseppe De Palma,Francesca Bruzzese,Alfredo Budillon,Claudio Napoli,Filomena de Nigris +5 more
TLDR
In this paper , the authors discuss potential mechanisms which may have contributed to the cancer regression in these cases and could be useful for future options in cancer treatment, including oncolytic and priming hypotheses.Abstract:
Abstract Early in the COVID-19 pandemic, it emerged that the risk of severe outcomes was greater in patients with co-morbidities, including cancer. The huge effort undertaken to fight the pandemic, affects the management of cancer care, influencing their outcome. Despite the high fatality rate of COVID-19 disease in cancer patients, rare cases of temporary or prolonged clinical remission from cancers after SARS-CoV-2 infection have been reported. We have reviewed sixteen case reports of COVID-19 disease with spontaneous cancer reduction of progression. Fourteen cases of remission following viral infections and two after anti-SARS-CoV-2 vaccination. The immune response to COVID-19, may be implicated in both tumor regression, and progression. Specifically, we discuss potential mechanisms which include oncolytic and priming hypotheses, that may have contributed to the cancer regression in these cases and could be useful for future options in cancer treatment. read more
Citations
More filters
Heat shock proteins may be a missing link between febrile infection and cancer tumor rejection via autoantigen molecular mimicry
TL;DR: In this paper , the authors performed epitope discovery between heat-shock proteins (HSP) and cancer-associated antigens (CAA) and annotated the results with experimentally validated epitopes in the Immune Epitope Database (IEDB).
References
More filters
Journal ArticleDOI
STATs in cancer inflammation and immunity: a leading role for STAT3
TL;DR: Signal transducer and activator of transcription proteins are central in determining whether immune responses in the tumour microenvironment promote or inhibit cancer, and STAT3 is a promising target to redirect inflammation for cancer therapy.
Journal ArticleDOI
The trinity of COVID-19: immunity, inflammation and intervention.
Matthew Zirui Tay,Chek Meng Poh,Laurent Rénia,Laurent Rénia,Paul A. MacAry,Lisa F. P. Ng,Lisa F. P. Ng,Lisa F. P. Ng +7 more
TL;DR: The interaction of SARS-CoV-2 with the immune system and the subsequent contribution of dysfunctional immune responses to disease progression is described and the implications of these approaches for potential therapeutic interventions that target viral infection and/or immunoregulation are highlighted.
Journal ArticleDOI
T cell exhaustion
TL;DR: Advances in the molecular delineation of T cell exhaustion are clarifying the underlying causes of this state of differentiation and also suggest promising therapeutic opportunities.
Journal ArticleDOI
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka,Howard L. Kaufman,Frances A. Collichio,Thomas Amatruda,Neil Senzer,Jason Chesney,Keith A. Delman,Lynn E. Spitler,Igor Puzanov,Sanjiv S. Agarwala,Mohammed M. Milhem,Lee D. Cranmer,Brendan D. Curti,Karl D. Lewis,Merrick I. Ross,Troy H. Guthrie,Gerald P. Linette,Gregory A. Daniels,Kevin J. Harrington,Mark R. Middleton,Wilson H. Miller,Jonathan S. Zager,Yining Ye,Bin Yao,Ai Li,Susan Doleman,Ari M. Vanderwalde,Jennifer Gansert,Robert Coffin +28 more
TL;DR: T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial and represents a novel potential therapy for patients with metastatic melanoma.
Journal ArticleDOI
An inflammatory cytokine signature predicts COVID-19 severity and survival.
Diane Marie Del Valle,Seunghee Kim-Schulze,Hsin-Hui Huang,Noam D. Beckmann,Sharon Nirenberg,Bo Wang,Yonit Lavin,Talia H. Swartz,Deepu Madduri,Aryeh Stock,Thomas U. Marron,Hui Xie,Manishkumar Patel,Kevin Tuballes,Oliver Van Oekelen,Adeeb Rahman,Patricia Kovatch,Judith A. Aberg,Eric E. Schadt,Sundar Jagannath,Madhu Mazumdar,Alexander W. Charney,Adolfo Firpo-Betancourt,Damodara Rao Mendu,Jeffrey S. Jhang,David Reich,Keith Sigel,Carlos Cordon-Cardo,Marc Feldmann,Samir Parekh,Miriam Merad,Sacha Gnjatic +31 more
TL;DR: It is proposed that serum IL-6 and TNF-α levels should be considered in the management and treatment of patients with COVID-19 to stratify prospective clinical trials, guide resource allocation and inform therapeutic options.